Announcements
Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal
On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, made this decision after new safety findings emerged from the ongoing SYMPHONY 1 clinical trial, which indicated a possible increased risk of secondary blood cancers when the drug was used in a specific combination regimen (lenalidomide and rituximab, also referred to as R2).
